Investment Thesis
Sana is a pre-commercial biotech company with no revenue and unsustainable cash burn of $144.8M annually against only $71.9M in cash reserves, implying sub-6-month runway. While the debt-free balance sheet and improving loss trajectory (EPS improved 17.2% YoY) are positive, fundamental financial health is severely compromised by lack of commercialization and operational sustainability.
Strengths
- Zero long-term debt provides financial flexibility and reduces solvency risk
- Improving loss trend with 17.2% YoY EPS improvement suggests operational discipline
- Healthy liquidity ratios (1.89x current and quick) with reasonable asset base of $416.9M
Risks
- Pre-commercial with zero revenue; company is entirely dependent on capital markets for survival
- Unsustainable cash burn of $144.8M annually with only $71.9M cash; critical funding urgency within months
- Negative returns on equity (-151.8%) and assets (-58.6%) indicate significant shareholder value destruction
Key Metrics to Watch
- Cash runway and financing activities (Form 8-K, prospectus filings)
- Operating cash burn rate trends and operating loss reduction pace
- Clinical trial milestones, regulatory submissions, and partnership announcements
Financial Metrics
Revenue
N/A
Net Income
-244.2M
EPS (Diluted)
$-0.96
Free Cash Flow
-144.8M
Total Assets
416.9M
Cash
71.9M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-151.8%
ROA
-58.6%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
1.89x
Quick Ratio
1.89x
Debt/Equity
0.00x
Debt/Assets
61.4%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-15T09:06:27.507210 |
Data as of: 2025-12-31 |
Powered by Claude AI